New US drug shortages this year are running roughly at the same levels as the last two years, and far below the record highs seen earlier this decade, the US FDA told in-Pharmatechnologist.
Fareva has bought an API plant in France from Merck & Co. and outlined plans to turn it into a high-potency actives site.
Nitroglycerin could make cancer drugs more effective say researchers trying to use the dynamite ingredient to help destroy tumours.
The US FDA has found no systemic issues affecting the safety or efficacy of generics clinically tested at GVK BioSciences, but says it supports Europe’s ban of around 700 products.
Novo Nordisk could spend up to $2bn (€1.8bn) on two facilities to support its diabetes portfolio, including an oral long-acting GLP-1 analogue set to enter Phase III trials.